Q2 2024 Hypera SA Earnings Call Transcript
Key Points
- Hypera SA (HYPMY) reported a 6.3% increase in sell-out for the quarter, driven by strong performance in chronic and preventive treatments.
- The company achieved a record operating cash flow of BRL624 million, aided by a significant reduction in inventory levels.
- Hypera SA (HYPMY) is making substantial investments in research, development, and innovation, allocating about 7% of net revenue to R&D.
- The company has been included in the FTSE for Good Index series, highlighting its commitment to sustainability.
- Hypera SA (HYPMY) reported a net income of BRL491 million from continuing operations, showcasing strong financial performance.
- The performance in respiratory, pain, fever, and influenza medication was negative, impacting overall growth.
- Despite price increases and reduced idle time, gross margins were pressured due to a higher share of generics and increased commercial discounts.
- The company faces a challenging competitive environment, particularly in the generics market, which has become more aggressive.
- Hypera SA (HYPMY) anticipates potential foreign exchange impacts in 2025 due to current high inventory levels.
- The company's leverage remains at 2.4 times the expected EBITDA, indicating a focus on deleveraging amidst high interest rates.
Good morning, ladies and gentlemen. Welcome to Hypera Pharma's earnings call for the second quarter of 2024. We have with us Mr. Breno Oliveira, CEO and Mr. Adalmario Couto, IRO.
This event is being recorded that video can be seen at the company's investor relations website, our ri.hypera.com.br. (Operator instructions) Before we proceed I would like to reinforce that some information in this conference call may contain projections or statements about future expectations. This information is subject to known and unknown risks and uncertainties that may cause them not to materialize or to be substantially different from what was expected.
I will now turn it over to Mr. Breno Oliveira. Mr. Oliveira, you have the floor.
Good morning, everyone. I'd like to thank you all for being here for our earnings presentation for the second quarter. I will begin discussing our growth on Slide 3. Our sell-out went up 6.3% this quarter, boosted especially by our performance in chronic and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
